Ashfaq Shuaib, M.D.
Professor – Neurology
Dr. Ashfaq Shuaib received his undergraduate medical education at Khyber Medical College in Pakistan, obtaining his MBBS degree in 1980. Thereafter, he then did post-graduate training in Internal Medicine and Neurology at the University of Calgary between 1983 and 1988, followed by specialized training in cerebrovascular research at the University of Western Ontario and Duke University Medical School in Durham, North Carolina.
He returned to Canada as an Assistant Professor in Medicine and Neurology at the University of Saskatoon in 1989 and rose rapidly through the academic ranks to be appointed full professor in July 1995. In addition, he held the position of Residency Program Director in the Division of Neurology between 1990 and 1995, supervised numerous research fellows and graduate students and was the Director of the Saskatchewan Stroke Research Centre and Director of the WHO Centre.
He joined the University of Alberta as Professor of Medicine and Director of the Division of Neurology effective September 1, 1997. In July 2007 he stepped down as Divisional Director but remained the Director of the Stroke Program. He moved to Doha in January 2014 as the Director of the Qatar Neuroscience Institute. His major interest is in the understanding of the basic mechanisms of cerebral ischemia and clinical trials in cerebrovascular diseases. He has published over 345 articles in peer-reviewed journals, has more than 700 abstracts at National and International conferences and his research is funded by the CIHR, Heart and Stroke Foundation of Alberta, NIH, AHFMR and the industry. He is on the editorial board of ‘Heart.Org’ ‘Stroke- an AHA journal’, Faculty F-1000, Frontiers in Neurology (associate editor), Neuro-hospitalist and Pakistan J of Neuroscience.
His translational research focuses on pathophysiological mechanisms and the treatment of acute stroke. He chaired the steering committees of large multicenter trials of the SAINT II and SENTIS trials and is currently in the steering committees of 5 large multicenter acute stroke trials. In Qatar he has started a clinical trial in patients with TIAs and minor stroke with 10 sites in Middle East as participating centers.